JJ
Top Ten most popular articles on Pharmafile.com this week
July 20, 2018Medical Communications GSK, ICR, J&J, JJ, Novartis, Trump, brexit, top 10
As Brexit negotions have hit a stalemate this week, the United Kingdom’s exit from the European Union has hit the …
J&J stops Invokana trial early after success in kidney disease and type 2 diabetes
July 17, 2018Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes
Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …
J&J ordered to pay $4.68 billion to talc-powder plaintiffs
July 13, 2018Medical Communications J&J, JJ, Johnson and Johnson, legal, talc powder
A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women …
Missouri appeals court overturns $55m J&J verdict
July 6, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Litigation, appeal, pharma
A $55 million verdict against the multinational pharmaceutical company Johnson & Johnson has been overturned by an appeals court in …
Top Ten most popular articles on Pharmafile.com this week
June 29, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Remicade, Roche, biosimilar Amgen, lung cancer, multiple sclerosis, pharma
Summer seems to be in full swing as we reach the end of June, so it’s time to look back …
J&J’s second-in-command to retire, alongside executive restructure
June 25, 2018Medical Communications, Sales and Marketing J&J, JJ, Johnson & Johnson, pharma
Johnson & Johnson’s Group Worldwide Chairman Sandra Peterson (pictured) has announced she is to retire from her role and the …
Janssen debuts promising new cancer data at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma
Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …
Top Ten most popular articles on Pharmafile.com this week
June 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, AstraZeneca, Cancer, Gilead, HIV, J&J, JJ, google, machine learning, melanoma, pharma, top ten
The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …
J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex
May 29, 2018Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq
Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …
Top Ten most popular articles on Pharmafile.com this week
May 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, GSK, J&J, JJ, Novartis, Shire, Takeda, Valeant, biotech, drugs, pharma, pharmaceutical
It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …
J&J’s ketamine-based antidepressant showed mixed success at Phase 3
May 8, 2018Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma
Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …
Top Ten most popular articles on Pharmafile.com this week
April 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical
It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …
Working Life: Kris Sterkens, Company Group Chairman, Janssen EMEA
April 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, Kris Sterkens, pharma
Pharmafile.com sat down with Kris Sterkens, Company Group Chairman of Janssen’s EMEA operations to discuss nearly three decades at the …
J&J pays out $37m in damages over claims its talc contains asbestos
April 6, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, mesothelioma, ovarian cancer, pharma, talc
Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out …
J&J’s longest-standing CFO finally steps down
March 21, 2018Medical Communications, Research and Development J&J, JJ, Johnson & Johnson, biotech, cfo, drugs, pharma, pharmaceutical
Johnson & Johnson have revealed that its Chief Financial Officer and Executive Vice President, Dominic J. Caruso, will retire from …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
